Ambeed.cn

首页 / / / mTOR / XL388

XL388 {[allProObj[0].p_purity_real_show]}

货号:A210267

XL388 is a potent and selective ATP-competitive mTOR inhibitor with IC50 value of 9.9 nM.

XL388 化学结构 CAS号:1251156-08-7
XL388 化学结构
CAS号:1251156-08-7
XL388 3D分子结构
CAS号:1251156-08-7
XL388 化学结构 CAS号:1251156-08-7
XL388 3D分子结构 CAS号:1251156-08-7
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

XL388 纯度/质量文件 产品仅供科研

货号:A210267 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]
JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]
BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]
J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]
PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]
更多 >
产品名称 mTOR mTORC1 mTORC2 其他靶点 纯度
AZD-8055 ++++

mTOR (truncated), IC50: 0.13 nM

mTOR (full length), IC50: 0.8 nM

99%+
Gedatolisib ++++

mTOR, IC50: 1.6 nM

98%
GSK1059615 ++

mTOR, IC50: 12 nM

98%
Vistusertib +++

mTOR, IC50: 2.8 nM

99%+
Torin 1 +++

mTOR, IC50: 4.32 nM

+++

mTORC1, IC50: 2 nM

++

mTORC2, IC50: 10 nM

DNA-PK 99%+
Dactolisib +++

mTOR (p70S6K), IC50: 6 nM

98+%
PI-103 +

mTOR, IC50: 30 nM

99%+
WAY-600 ++

mTOR, IC50: 9 nM

99%
Voxtalisib +

mTOR, IC50: 157 nM

99%+
PF-04691502 ++

mTOR, Ki: 16 nM

98+%
Onatasertib ++

mTOR, IC50: 16 nM

DNA-PK 99%+
Chrysophanol EGFR 98%
Samotolisib DNA-PK 99%+
Torkinib +++

mTOR, IC50: 8 nM

PDGFR,DNA-PK 99%+
Everolimus 99%+
WYE-354 +++

mTOR, IC50: 5 nM

98%
Tacrolimus 98%
PP121 ++

mTOR, IC50: 13 nM

PDGFR,VEGFR 99%+
Torin 2 ++++

mTOR, IC50: 0.25 nM

DNA-PK 99%+
Rapamycin ++++

mTOR, IC50: ~0.1 nM

98%
GDC-0349 +++

mTOR, Ki: 3.8 nM

98%
XL388 ++

mTOR, IC50: 9.9 nM

+++

mTORC1, IC50: 8 nM

+

mTORC2, IC50: 166 nM

99%+
WYE-687 +++

mTOR, IC50: 7 nM

98+%
Apitolisib +

mTOR, Ki app: 17 nM

98%+
WYE-132 ++++

mTOR, IC50: 0.19 nM

99%+
Sapanisertib ++++

mTOR, Ki: 1.4 nM

99%+
BGT226 maleate 99%+
ETP-46464 ++++

mTOR, IC50: 0.6 nM

DNA-PK 98%
PI3K-IN-1 +

mTOR, IC50: 157 nM

98+%
Zotarolimus +++

FKBP-12, IC50: 2.8 nM

99+%
OSI-027 +++

mTOR, IC50: 4 nM

+

mTORC1, IC50: 22 nM

+

mTORC2, IC50: 65 nM

99%+
Ridaforolimus ++++

mTOR, IC50: 0.2 nM

99%+
Temsirolimus +

mTOR, IC50: 1.76 μM

95%
CZ415 ++

mTOR, pIC50: 8.07

99%+
SF2523 +

mTOR, IC50: 280 nM

DNA-PK 99%+
KU-0063794 ++

mTORC1, IC50: ~10 nM

++

mTORC2, IC50: ~10 nM

99%+
Omipalisib ++++

mTORC1, Ki: 0.18 nM

++++

mTORC2, Ki: 0.3 nM

99%+
Palomid 529 99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

XL388 生物活性

靶点
  • mTORC1

    mTORC1, IC50:8 nM

  • mTORC2

    mTORC2, IC50:166 nM

  • mTOR

    mTOR, IC50:9.9 nM

描述 The mammalian target of rapamycin (mTOR) is a large protein kinase that integrates both extracellular and intracellular signals of cellular growth, proliferation, and survival, which lies in two different multi-protein complexes, including mTOR complex 1(mTORC1) and mTORC2. XL388 is an orally bioavailable inhibitor of the mTOR that inhibits cellular phosphorylation of mTOR complex 1 (p-p70S6K, pS6, and p-4E-BP1) and mTOR complex 2 (pAKT (S473)) substrates, with IC50 value of 9.9 nM[4]. XL388(5-200nM)-treated MG-63 cells showed increased percentage of G1 phase and decreased S phase and G2-M phase compared with untreated cells. Oral administration of XL388 (20 mg/kg body weight, every three days, × 7 times) significantly inhibited human osteosarcoma cell line U2OS xenograft growth in severe combined immuno-defcient mice more than 40%[5]. XL388 (10-1000 nM, 24-96 h) dose- and time-dependently induced renal cell carcinoma cell line 786-0 cell death. Consistently, oral administration of XL388 (20 mg/kg, every three days, × 7 times) dramatically inhibited 786-0 tumor growth in nude mice more than 60%[6].
作用机制 XL388 inhibits mTOR activity in an ATP-competitive manner.

XL388 动物研究

Dose Mice: 20 mg/kg[2] (p.o.); 10 mg/kg[1] (i.v.); 50 mg/kg[3] (i.p.) Rat: 3 mg/kg[1] (i.v./p.o.) Dog: 3 mg/kg[1] (i.v./p.o.)
Administration p.o., i.v.
Pharmacokinetics
Animal Mice[1] Rats[1] Dogs[1] Monkeys[1]
Dose 10 mg/kg 3 mg/kg 3 mg/kg 3 mg/kg
Administration i.v. or p.o. i.v. or p.o. i.v. or p.o. i.v. or p.o.
F 31.4% (p.o.) 25.6% (p.o.) 69.6% (p.o.) 53.4% (p.o.)
T1/2 1.35 h (i.v.) 0.45 h (i.v.) 0.45 h (i.v.) 0.86 h (i.v.)
Tmax 0.5 h (p.o.) 0.5 h (p.o.) 6.11 h (p.o.) 2.0 h (p.o.)
CL 2.75 L/kg/h (i.v.) 1.27 L/kg/h (i.v.) 0.598 L/kg/h (i.v.) 5.05 L/kg/h (i.v.)
Cmax 9.14 μM (i.v.)
1.30 μM (p.o.)
4.12 μM (i.v.)
0.707 μM (p.o.)
2.28 μM (i.v.)
1.66 μM (p.o.)
0.95 μM (i.v.)
0.25 μM (p.o.)
AUC0→∞ 8.00 μM·h (i.v.)
2.51 μM·h (p.o.)
3.72 μM·h (i.v.)
0.952 μM·h (p.o.)
11.0 μM·h (i.v.)
7.66 μM·h (p.o.)
1.31 μM·h (i.v.)
0.70 μM·h (p.o.)
Vss 1.96 L/kg (i.v.) 1.27 L/kg (i.v.) 3.15 L/kg (i.v.) 6.42 L/kg (i.v.)

XL388 参考文献

[1]Takeuchi CS, Kim BG, et al. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J Med Chem. 2013 Mar 28;56(6):2218-34.

[2]Zhu YR, Zhou XZ, et al. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Oncotarget. 2016 Aug 2;7(31):49527-49538.

[3]Yu K, Toral-Barza L, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40.

[4]Takeuchi CS, Kim BG, Blazey CM, Ma S, Johnson HW, Anand NK, Arcalas A, Baik TG, Buhr CA, Cannoy J, Epshteyn S, Joshi A, Lara K, Lee MS, Wang L, Leahy JW, Nuss JM, Aay N, Aoyama R, Foster P, Lee J, Lehoux I, Munagala N, Plonowski A, Rajan S, Woolfrey J, Yamaguchi K, Lamb P, Miller N. Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR). J Med Chem. 2013 Mar 28;56(6):2218-34. doi: 10.1021/jm3007933. Epub 2013 Mar 7. PMID: 23394126.

[5]Zhu YR, Zhou XZ, Zhu LQ, Yao C, Fang JF, Zhou F, Deng XW, Zhang YQ. The anti-cancer activity of the mTORC1/2 dual inhibitor XL388 in preclinical osteosarcoma models. Oncotarget. 2016 Aug 2;7(31):49527-49538. doi: 10.18632/oncotarget.10389. PMID: 27385099; PMCID: PMC5226526.

[6]Xiong Z, Zang Y, Zhong S, Zou L, Wu Y, Liu S, Fang Z, Shen Z, Ding Q, Chen S. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent. Oncotarget. 2017 May 2;8(18):30151-30161. doi: 10.18632/oncotarget.15620. PMID: 28404914; PMCID: PMC5444733.

XL388 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

10.98mL

2.20mL

1.10mL

21.95mL

4.39mL

2.20mL

XL388 技术信息

CAS号1251156-08-7
分子式C23H22FN3O4S
分子量 455.502
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

溶解度

DMSO: 50 mg/mL(109.77 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方

30% PEG400+0.5% Tween80+5% propylene glycol+water 30 mg/mL suspension

Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。